The global allogeneic cell therapy devices market size is estimated at USD 408.12 million in 2024, grew to USD 511.30 million in 2025 and is predicted to surpass around USD 3,886.96 million by 2034, expanding at a CAGR of 25.28% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allogeneic Cell Therapy Devices Market
5.1. COVID-19 Landscape: Allogeneic Cell Therapy Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allogeneic Cell Therapy Devices Market, By Therapy Type
8.1. Allogeneic Cell Therapy Devices Market Revenue and Volume, by Therapy Type, 2024-2034
8.1.1. Stem Cell Therapies
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Non-stem Cell Therapies
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Allogeneic Cell Therapy Devices Market, By Therapeutic Area
9.1. Allogeneic Cell Therapy Devices Market Revenue and Volume, by Therapeutic Area, 2024-2034
9.1.1. Hematological Disorders
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Dermatological Disorders
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Allogeneic Cell Therapy Devices Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
Chapter 11. Company Profiles
11.1. SSM Cardinal Glennon Children's Medical Center
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Cleveland Cord Blood Center
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Duke University School of Medicine
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. New York Blood Center
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Clinimmune Labs, University of Colorado Cord Blood Bank
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. MD Anderson Cord Blood Bank
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. LifeSouth Community Blood Centers, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bloodworks Northwest
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. JCR Pharmaceuticals Co., Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Sumitomo Pharma Co., Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample